Lineage Cell Therapeutics Q2 Highlights: $1.1M Revenue, $50.8M Cash

Lineage Cell Therapeutics (LCTX) released its Q2 2026 earnings, reporting $1.1 million in revenue and a net income of $1.5 million, attributed to a non-cash warrant-liability gain. The company ended the quarter with $50.8 million in cash and marketable securities, extending its financial runway into Q3 2028. Progress was noted in preclinical programs for corneal disease, Type 1 diabetes, and hearing loss, while OpRegen is eligible for up to $615 million in development milestones. This financial position and pipeline advancements suggest potential for future growth, which may be significant for investors considering biotech opportunities.